The diagnosis of an acute episode of infections mononucleosis (IM) is made on the basis of clinical symptoms and serological evidence for development of heterophile antibodies. In an effort to obtain a very sensitive and specific assay for diagnosis of IM, we have developed MERISTAR:IM. The MERISTAR assay uses latex beads coated with purified bovine heterophile antigen. We compared the sensitivity and specificity and performance characteristics of the latex-based test to those of the commercially available erythrocyte-based Monospot test with serum samples from 363 suspected-IM patients and controls. A total of 28 samples from patients with confirmed IM were positive with the MERISTAR assay, while only 23 of the samples were positive with the Monospot assay. The two assays had equal specificity, as each test gave two false-positive results. In the technical performance of the assay, the MERISTAR assay was simpler and faster to perform than the Monospot assay.
The diagnosis of acute infectious mononucleosis (IM) is made on the basis of a combination of symptoms and the presence of the serologic evidence of exposure to the Epstein-Barr virus (EBV). Because the major symptoms of acute IM, such as pharyngitis, rash, fever, jaundice with elevated liver enzymes, lymphadenopathy, and splenomegaly are not specific for IM, serological evidence of EBV infection is necessary to confirm all suspected-IM cases (6) . Assays which detect antibody response to EBV-specific antigens are not easily performed and are often unavailable in many clinical laboratories. In addition to antibodies specific for virus-encoded antibodies, most individuals with acute IM also produce antibodies against the Paul-Bunnell heterophile antigen present on horse, sheep, and bovine erythrocytes (8) . Rapid slide and tube assays (5) which detect the heterophile antibody response are easily performed and readily available but lack sensitivity or require absorbent techniques to remove cross-reacting non-IM heterophile antibodies (e.g., Forssman antibodies). At least 10% of all adult individuals with acute IM and a larger percentage of children with acute IM have no measurable heterophile response by the currently available methodologies (3) . We developed a latex-based assay (MERISTAR: IM; Meridian Diagnostics, Cincinnati, Ohio) to rapidly detect Paul-Bunnell heterophile-specific antibodies by their ability to agglutinate uniform latex particles sensitized with purified bovine mononucleosis antigen (10) . The new assay was evaluated by comparing the reactivities of sera from 305 suspected-IM patients and 40 control patients by using the MERISTAR latex and the currently available commercial Monospot test (1; Ortho Diagnostics, Inc., Raritan, N.J.). The assay specificity for acute IM episodes was evaluated by testing sera from an additional 18 patients with clinical conditions associated with elevated EBV serologies.
MATERIALS AND METHODS
Selection of test sera. Test sera were obtained from samples from suspected-IM patients which had been submitted to the Clinical Immunology Laboratory (North Carolina Memorial Hospital). A total of 305 samples were obtained from patients with clinical symptoms consistent with acute IM. The samples came from three groups of patients; 226 of the patients were hospital in-and outpatients, 38 of the patients were from the university student health service, and 41 of the patients were from a pediatric clinic. All samples were drawn from patients within a week from the onset of clinical symptoms.
Negative control serum samples from two groups of patients were used to test the specificity of the MERISTAR assay. In the first group were 40 individuals with a variety of infectious or malignant diseases, including systemic lupus erythematosus, rheumatoid arthritis, toxoplasmosis, Rocky Mountain spotted fever, Legionnaires disease, brucellosis, influenza, and lymphocytic leukemia. The second group contained 18 patients with diseases known to be associated with elevated EBV antibody titers. Patients in this group had chronic mononucleosis, hemophilia, nasopharyngeal carcinoma, Chédiak-Higashi disease (accelerated phase), heterophile-negative acute IM (one case), or an immunocompromised state with a secondary EBV infection. All the sera from this group of patients were negative for heterophile antibody (Monospot assay) and positive for EBV antibodies. All sera had viral capsid antigen (VCA) immunoglobulin G (IgG) titers greater than 1:640 and Epstein-Barr nuclear antigen (EBNA) titers greater than 1:10. VCA IgM titers were greater than 1:10 in 14 of the sera, and early antigen (EA) titers were greater than 1:10 in 15 of the sera.
Classification of patient diagnosis. The hospital medical records of all patients with positive heterophile tests were examined to determine the clinical symptoms and length of time between the onset of symptoms and blood collection. When the heterophile-positive sera were absorbed according to the Davidsohn differential assay, the specificity of both assays was confirmed in 13 samples, whereas the 8 remaining samples with low heterophile titers did not demonstrate antibody activity after the absorption. It could not be determined whether the lack of reactivity after absorption was due to the dilution of the sample during the absorption step or due to absorption of a nonspecific antibody. Of these eight serum samples, four had EBV titers consistent with IM, three had negative EBV titers, and une was insufficient for EBV serological testing.
A general trend of a two-to fourfold-higher titer was seen with the MERISTAR test compared with the Monospot, although a higher MERISTAR titer was not always seen in the sera which were positive with both tests. When the titers of the 21 samples that were positive with both kits was compared, 13 samples had a higher titer with the MERI- Overall, these results demonstrate a higher sensitivity for the latex-based kit and equal specificities for the two methods. In other erythrocyte-based heterophile IM assays, increased sensitivity has increased the number of falsepositive reactions (5) . In our evaluation of the MERISTAR assay, we did not see an increase in false-positive reactions with an increased sensitivity of the assay.
A major problem inherent in the determination of the sensitivity and specificity of assays developed to assist in the diagnosis of IM is the difficulty in distinguishing patients with EBV-related IM from other patients with similar presenting symptoms (6) . In addition to the difficulty of making a specific clinical diagnosis, assays which detect EBV antibody response are difficult to perform and interpret and are sometimes negative in young children. We attempted to establish a diagnosis of IM based on a combination of EBV serologies and the clinical diagnosis which consisted of presenting symptoms, leukocyte count and differentials, and liver enzyme levels. The patients with positive MERISTAR tests and negative Monospot tests showed some evidence of abnormalities in some of the measured parameters, and all but one of them showed evidence of exposure to EBV, but none of them had classical IM. Thus, the availability of the latex-based assay which uses purified heterophile antigen which should be specific for Paul-Bunnell heterophilespecific antibodies may lead to an enhanced ability to distinguish atypical IM from other syndromes with similar presenting symptoms. Further work must be done to establish the absolute specificity of the latex-based test, but the test is very useful for screening patients with IM-like symptoms.
A second problem with the determination of sensitivity and specificity of the IM heterophile kit assays is that most evaluations are done on single serum samples from suspected-IM patients (5, 12) . The time course for the appearance of heterophile and EBV-specific antibodies during an acute IM episode may vary depending on the specificities of the antibodies detected (7) . A false-negative result may therefore be due to a combination of the detection method used and the time of collection of the blood sample. A sequential study of the MERISTAR heterophile titers of individuals exposed to EBV is thus necessary to determine if the increased sensitivity of the assay is due to earlier and/or longer detection of the heterophile antibodies in the serum of patients with acute IM.
Two technical aspects of the MERISTAR test made it clearly superior to any of the currently available assays. The first was the ease of performance of the test. A single drop of serum was mixed directly with the latex reagent and rotated for 2 min; thus, the MERISTAR test was much simpler to perform than the Monospot test. In addition, the agglutination was more easily read, with a sharper distinction between positive and negative results. The second desirable aspect of the MERISTAR test was the ability to do multiple samples at once. As many as 20 samples could be done on a large slide at a single time; therefore, the time required to do multiple samples was much less overall.
